Wainua Injection, Solution
Product Images NDC 0310-9400

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Wainua (NDC 0310-9400). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton_label_45mg_per_0.8ml (Carton Label 45mg Per 0.8ml)

Packaging label for WAINUA (eplontersen) injection, 45 mg/0.8 mL, a subcutaneous injection by AstraZeneca Pharmaceuticals LP. The label indicates a single-dose autoinjector in 0.8 mL solution. Storage instructions specify refrigeration at 2°C to 8°C (36°F to 46°F), avoiding freezing and heat exposure. The label includes branding, dosage strength, and NDC number 0310-9400-01.*

FDA Label Image

Picture_4 (Picture 4)

An instructional illustration showing two items used for injection site care: a cotton ball or gauze pad on the left and a small adhesive bandage on the right.*

FDA Label Image

Chemical_structure (Chemical Structure)

Chemical structure diagram showing the molecular structure of eplontersen, the active ingredient in WAINUA injection, solution. The diagram depicts the nucleotide sequences and chemical bonds characteristic of this compound.*

FDA Label Image

Figure_1 (Figure 1)

A line graph comparing the LS Mean (SEM) change from baseline in mNIS+7 scores over 35 weeks between WAINUA and placebo groups. The x-axis represents time from baseline to week 35, while the y-axis shows the change in scores. WAINUA maintains a near-zero change, whereas placebo shows an increase. Sample sizes at week 35 are 140 for WAINUA and 59 for placebo.*

FDA Label Image

Figure_2 (Figure 2)

A bar graph comparing the percent of patients experiencing changes in mNIS+7 scores from baseline at Week 35 for WAINUA versus placebo. The x-axis shows score changes ranging from -90 to +60, along with categories for Death and Missing, while the y-axis represents the percent of patients. Data distinguishes better and worse outcomes with black bars for WAINUA (N=144) and white bars for placebo (N=60).*

FDA Label Image

Figure_3 (Figure 3)

A line graph comparing the change from baseline in Norfolk QOL-DN total score over 35 weeks between WAINUA 45 mg subcutaneous injection and placebo groups. The graph shows a decrease in score for WAINUA and an increase for placebo, with sample sizes of 133 for WAINUA and 58 for placebo at both baseline and week 35.*

FDA Label Image

Figure_4 (Figure 4)

A bar chart comparing percentage of patients showing Norfolk QOL-DN total score change from baseline at Week 35 between WAINUA and placebo groups. The x-axis shows score change categories ranging from -70 to +50, death, and missing data. The y-axis shows percent of patients. Bars represent better (negative scores) and worse (positive scores) outcomes for WAINUA and placebo groups.*

FDA Label Image

Picture_10 (Picture 10)

Instructional diagram showing three steps for subcutaneous injection using a pen device. Step a) 'Place' the device at a 90-degree angle against the skin. Step b) 'Push' the device down until a click is heard. Step c) 'Hold' the device steady for 10 seconds to complete the injection.*

FDA Label Image

Picture_11 (Picture 11)

An instructional illustration depicting two steps in using a subcutaneous injection pen. Panel a) shows pressing the device down for injection; panel b) shows lifting the device upwards, highlighting the orange plunger rod movement.*

FDA Label Image

Picture_12 (Picture 12)

An instructional illustration showing a hand holding a prefilled injection pen with an orange cap, positioned above a sharps disposal container. The image demonstrates the proper disposal of the used injection pen into the container.*

FDA Label Image

Picture_2 (Picture 2)

An instructional diagram of a subcutaneous injection pen labeled with internal components including the plunger, viewing window, medicine reservoir, clear cap, and orange needle shield. The illustration visually identifies parts relevant to administering a solution injection.*

FDA Label Image

Picture_3 (Picture 3)

An instructional illustration showing a small alcohol wipe packet on the left and a red sharps disposal container on the right, used in the context of safe injection practices.*

FDA Label Image

Picture_5 (Picture 5)

An illustration of a stopwatch showing a 30-minute wait time. The stopwatch face is divided with a blue segment indicating the elapsed portion up to 30 minutes. The word "Wait" is displayed above the stopwatch. This graphic likely instructs users to wait for 30 minutes after an action related to the product.*

FDA Label Image

Picture_6 (Picture 6)

An instructional diagram showing a close-up view of a check window on a WAINUA (eplontersen) injection pen, displaying a color change indicator and an expiration date box labeled EXP: MM/YYYY. The diagram highlights the check indicator used to verify medication status before subcutaneous injection.*

FDA Label Image

Picture_7 (Picture 7)

An instructional diagram showing recommended injection sites for WAINUA (Eplontersen) subcutaneous injection. The diagram highlights areas on the front and side of a human body, including the stomach (abdomen), thigh, back of the upper arm, and shoulders as appropriate locations for administration. Separate sections indicate sites safe for self-administration and those for caregivers only.*

FDA Label Image

Picture-8 (Picture 8)

An instructional illustration showing handwashing with water and soap on the left and applying a patch or dressing to the skin on the right. The images demonstrate hygiene and skin preparation steps.*

FDA Label Image

Picture_9 (Picture 9)

An instructional illustration showing a person's hands removing a clear cap from a WAINUA injection pen and revealing the needle shield, demonstrating preparation for subcutaneous injection.*

FDA Label Image

Picture_1 (Picure 1)

WAINUA 45 mg/0.8 mL injection solution in a subcutaneous delivery cartridge, shown as a clear container partially filled with liquid and capped by an orange end. The labeler is AstraZeneca Pharmaceuticals LP.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.